Imunon, Inc. Cash Flow Statement
IMNN|7 years of annual SEC 10-K data (FY2015-FY2023)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
Imunon, Inc. used $23M in operating cash flow and negative free cash flow of $23M in FY2023.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2015 |
|---|---|---|---|---|---|---|---|
| Net Income | -$35.9M | -$20.8M | -$21.5M | -$16.9M | -$11.9M | -$20.4M | -$8.3M |
| Depreciation & Amortization | $197.0K | $702.9K | $741.5K | $721.7K | $356.9K | $553.0K | $339.2K |
| Operating Cash Flow | -$23.1M | -$16.2M | -$15.6M | -$20.3M | -$7.0M | -$16.6M | -$9.5M |
| Capital Expenditures | $267.8K | $311.6K | $19.1K | $349.2K | $138.4K | $38.6K | $57.5K |
| Free Cash Flow | -$23.4M | -$16.5M | -$15.6M | -$20.6M | -$7.2M | -$16.7M | -$9.6M |
| FCF Margin | -4672.9% | -3307.0% | -3127.6% | -4121.6% | -1436.0% | -3336.1% | -7666.2% |